%0 Journal Article
%T Preclinical studies of [61Cu]ATSM as a PET radiopharmaceutical for fibrosarcoma imaging
%A Amir R. Jalilian
%A Nima Rostampour
%A Pejman Rowshanfarzad
%A Kamaleddin Shafaii
%A Mohsen Kamali-Dehghan
%A Mehdi Akhlaghi
%J Acta Pharmaceutica
%@ 1846-9558
%D 2009
%I 
%R 10.2478/v10007-009-0008-9
%X [61Cu]diacetyl-bis(N4-methylthiosemicarbazone) ([61Cu] ATSM) was prepared using in house-made diacetyl-bis(N4-methylthiosemicarbazone) (ATSM) ligand and [61Cu]CuCl2 produced via the natZn(p, x)61Cu (180 ¦ÌA proton irradiation, 22 MeV, 3.2 h) and purified by a ion chromatography method. [61Cu]ATSM radiochemical purity was >98 %, as shown by HPLC and RTLC methods. [61Cu]ATSM was administered into normal and tumor bearing rodents for up to 210 minutes, followed by biodistribution and co-incidence imaging studies. Significant tumor/non-tumor accumulation was observed either by animal sacrification or imaging. [61Cu]ATSM is a positron emission tomography (PET) radiotracer for tumor hypoxia imaging.
%K radiopharmaceuticals
%K copper-61
%K [61Cu]ATSM hypoxia
%K positron emission tomography
%K fibrosarcoma
%K imaging
%U http://versita.metapress.com/content/mg813272441r6122/?p=e23b13a363df4ecabe5fbbbf469787e5&pi=3